• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

2 Minute Medicine Rewind March 1 – March 8, 2015

byNeal YuanandDavid Ouyang
March 9, 2015
in Cardiology, Chronic Disease, Infectious Disease, Public Health, Surgery, Weekly Rewinds
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn

In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week.

Long-Term Efficacy of a Hepatitis E Vaccine

Hepatitis E virus (HEV) is most frequently a waterborne infection in resource-limited countries that can result in acute hepatitis and death especially in pregnant women. To-date there have been two separate vaccines that have been shown in clinical trials to have short-term efficacy. This is the first trial to establish longer-term efficacy of one of these vaccines. In this randomized control trial, researchers randomized 56,302 patients to receive the hepatitis E vaccine and 56,302 patients to receive a hepatitis B vaccine control. After a 4.5-year study period, there were 7 cases of hepatitis E in the vaccine group (0.3 cases per 10,000 person-year) and 53 cases in the control group (2.1 cases per 10,000 person-years), which translated to an 86.8% (95% CI 71-94) vaccine efficacy rate. When examined serologically, it was found that of the patients who were seronegative at baseline, 87% of patients receiving three doses of the hepatitis E vaccine displayed antibodies after 4.5 years, compared with 9% of patients in the control group. This study therefore that a hepatitis E vaccine induced effective antibody protection that was sustained after 4.5 years.

Effect of Sedative Premedication on Patient Experience After General Anesthesia

Premedication of patients, especially those with anxiety, using benzodiazepines before surgery is a routine practice thought to help improve the perioperative experience and ultimately operative outcomes. However, there is little clear evidence supporting this practice. In this randomized control trial, 1062 adult patients undergoing elective surgeries under general anesthesia were randomized to receive either 2.5mg of lorazepam, no premedication, or placebo prior to surgery. Investigators found that premedication with lorazepam did not significantly improve overall patient satisfaction as measured by EVAN-G, a validated patient satisfaction questionnaire (score of 72 (95% CI 70-73) for lorazepam vs. 73 (71-74) for no premedication vs. 71 (70-73) for placebo, p=0.38). There was similarly also no statistically significant improvement in patient satisfaction when looking only at patients with heightened preoperative anxiety. There were, however, differences in time to extubation and rate of early cognitive recovery. Time to extubation was 17 minutes (95% CI 14-20 min.) for the lorazepam group, 12 minutes (11-13) for the no premedication group, and 13 minutes (12-14) for the placebo group (p < 0.001). The rate of early cognitive recovery was 51% (95% CI 45-56%), 71% (66-77%), and 64% (59-69%) for the three groups respectively (p < 0.001). This study therefore shows that among patients who underwent general anesthesia for elective surgery, premedication with lorazepam did not improve patient satisfaction but did result in prolonged times of extubation and lower rates of early cognitive recovery.

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

RELATED REPORTS

Frailty in older adults with atrial fibrillation is multifactorial and associated with metabolic and cognitive factors

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

Digoxin is still widely used for rate control in patients with atrial fibrillation (AF) despite mounting evidence suggesting that it is associated with increased mortality in these patients. Still, though, there remains little robust randomized trial data supporting this perspective. Researchers did a retrospective analysis of patients from the ROCKET AF trial, which originally studied warfarin versus rivaroxaban for preventing stroke and embolic events in AF. Investigators found that out of the 14,171 patients in ROCKET AF, digoxin was used in 37% of patients and that patients were more likely to receive digoxin if they were female, had a history of heart failure, diabetes, or persistent AF. Digoxin was associated with increased all-cause mortality (5.41 vs. 4.30 events per 100 patient years, HR 1.17, 95% CI 1.04-1.32, p=0.0093), vascular death (3.55 vs. 2.69, 1.19, 1.03-1.39, p=0.0201), and sudden death (1.68 vs. 1.12, 1.36, 1.08-1.70, p=0.0076). This study therefore shows the continued widespread usage of digoxin for AF and additionally supports the association between digoxin and an increase in mortality, vascular death, and sudden death in these patients.

Association of Improved Air Quality with Lung Development in Children

Stricter air quality control policies in southern California over the last few decades have significantly decreased air pollution levels. This paper studies in more detail the effects of this pollution reduction on lung health in children. Researchers measured lung function annually in 2120 children who were part of one of three cohorts from different time periods (1994-1998, 1997-2001, 2007-2011) with a median starting age of 11 years. Investigators found that improvements across the three cohorts in 4-year growth of both FEV1 and FVC was significantly associated with declining levels of nitrogen dioxide (p<0.001 for FEV1 and FVC) and particulate matter with diameters < 2.5 μm (p=0.008 for FEV1 and p<0.001 for FVC) and < 10 μm (p<0.001 for FEV1 and FVC). Additionally, the proportion of children with clinically low FEV1 (FEV< 80% of predicted) at 15 years old, also fell significantly from 7.9% to 6.3% to 3.6% across the three time periods (p = 0.001). This study therefore shows that improvements in air quality were significantly associated with healthier lung development in children.

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

Chikungunya, a mosquito-transmitted disease that cause high fevers and enduring polyarthralgias, is now spreading broadly across the globe and into the US and Europe. However, there remains no disease specific treatment or vaccine for this disease. In this phase 1 trial, investigators studied the first candidate Chikungunya vaccine. 42 patients were randomized to receive a low dose, medium dose, or high dose of the live recombinant measles-virus-based candidate vaccine or a measles-mumps-rubella vaccine control. Scientists found that after one immunization, the vaccine raised neutralizing antibodies in all dosage groups with seroconversion rates of 44%, 92%, and 90% in the low, medium, and high dose groups respectively. After a second immunization, there was 100% seroconversion across all dose groups. There were no serious adverse events recorded. This vaccine is the first chikungunya vaccine to demonstrate good immunogenicity with an acceptable safety profile in humans and is a promising candidate for further studies.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anesthesiaatrial fibrillationdigoxinhepatitis
Previous Post

Improved air quality linked to better lung function in children

Next Post

Etiology of pediatric bacteremia and empiric treatment time vary

RelatedReports

An anatomical illustration of a heart with an electrocardiogram line and a catheter, indicating atrial fibrillation ablation procedures.
Cardiology

Frailty in older adults with atrial fibrillation is multifactorial and associated with metabolic and cognitive factors

September 30, 2026
A man is sleeping on his side with a caution symbol and tape beside him, while lung images are in the background, suggesting a focus on sleep and respiratory health.
Cardiology

Increased rapid eye movement (REM) sleep is associated with lower risks of several chronic diseases

September 23, 2026
A mother and child walk together along a path depicting recovery, with a hospital, home, clock, and sneakers symbolizing pediatric surgery recovery.
Imaging and Intervention

The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar

September 18, 2026
A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Next Post
Etiology of pediatric bacteremia and empiric treatment time vary

Etiology of pediatric bacteremia and empiric treatment time vary

Newer antidepressant use in pregnancy not linked to childhood asthma

Vegetarian diet may lower incidence of colorectal cancer

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.